Novartis’ former chief medical officer John Tsai has returned to a senior position in biopharma, taking the role of chief executive of UK start-up Forcefield Therapeutics.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh